Clinical Trial Update: I-125 Versus Pd-103 for Low Risk Prostate Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial update comparing Iodine-125 seeds with Palladium-103 seeds for low-risk prostate cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Iodine-125 brachytherapy seed (Iodine-125)
• Palladium-103 brachytherapy seed (Palladium-103)

Snippet

Sponsor: VA Puget Sound Health Care System | Conditions: Prostate Cancer | Phase 3 | Status: UNKNOWN